“A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)”, J of Skin, vol. 6, no. 6, pp. 482–496, Nov. 2022, doi: 10.25251/skin.6.6.5.